selegiline has been researched along with Disease Exacerbation in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (41.67) | 18.2507 |
| 2000's | 10 (27.78) | 29.6817 |
| 2010's | 11 (30.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Auinger, P; Cain, KC; Ginghina, C; Kang, UJ; Liu, C; Mattison, HA; McDermott, MP; Shi, M; Stewart, T; Zhang, J | 1 |
| Miklya, I | 1 |
| Luo, S | 1 |
| Auinger, P; Cain, KC; Cholerton, B; Ginghina, C; Liu, C; Shi, M; Stewart, T; Zhang, J | 1 |
| Müller, T | 1 |
| Chen, G; Luo, S | 1 |
| Bakota, L; Gulya, K; Gulyás, B; Halldin, C; Hermecz, I; Horváth, MC; Kása, P; Keller, E; Magyar, K; Nag, S; Pavlova, E; Várszegi, S | 1 |
| Au, WL; Li, SC; Luo, N; Seah, SH; Tan, LC; Wee, HL; Zhao, YJ | 1 |
| Ascherio, A; Auinger, P; Chen, H; Eberly, S; Huang, X; Mailman, R; Oakes, D; Schwarzschild, M | 1 |
| Holford, NH; Nutt, JG; Vu, TC | 2 |
| Double, K; Gerlach, M; Reichmann, H; Riederer, P | 1 |
| Hatakeyama, Y; Nakano, N; Yoshida, T | 1 |
| Nielsen, KK; Stimpel, H; Werdelin, LM; Winge, K | 1 |
| Hägglund, J; Heinonen, E; Kaugesaar, T; Mäki-Ikola, O; Pålhagen, S; Palm, R | 1 |
| Chan, PL; Holford, NH; Kieburtz, K; Nutt, JG; Shoulson, I | 1 |
| Jain, S; Lo, SE | 1 |
| Lang, AE; Marras, C; McDermott, MP; Naglie, G; Rochon, PA; Tanner, CM | 1 |
| Desser, H; Gerlach, M; Riederer, P; Youdim, MB | 1 |
| Cotman, CW; Ernesto, C; Growdon, J; Grundman, M; Klauber, MR; Pfeiffer, E; Sano, M; Schafer, K; Schneider, LS; Thal, LJ; Thomas, RG; Woodbury, P | 1 |
| Schulzer, M | 1 |
| Adelman, A | 1 |
| Demuth, M; Götz, ME; Koutsilieri, E; Riederer, P; Sauer, U; Sopper, S; ter Meulen, V | 1 |
| Brooks, DJ; Brunt, ER; Korczyn, AD; Poewe, WH; Rascol, O; Stocchi, F | 1 |
| Hägglund, J; Heinonen, EH; Kaugesaar, T; Kontants, H; Mäki-Ikola, O; Pålhagen, S; Palm, R; Turunen, J | 1 |
| Shoulson, I | 1 |
| Boyce, S; Carlson, E; Hill, RG; Martin, JE; Rupniak, NM; Webb, JK | 1 |
| Hauser, RA; Zesiewicz, TA | 1 |
| Boas, J; Erdal, JE; Larsen, JP | 1 |
| Stacy, M | 1 |
| Busenbark, K; Hauser, RA; Hubble, JP; Koller, WC; Malapira, T; Olanow, CW | 1 |
| Giladi, N; Kandinov, B; Korczyn, AD; Orlov, Y; Paleacu, D; Shabtai, H; Simon, ES; Treves, TA | 1 |
| Goetz, CG; Leurgans, S; Raman, R | 1 |
7 review(s) available for selegiline and Disease Exacerbation
| Article | Year |
|---|---|
Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Catechols; Disease Progression; Humans; Indans; Monoamine Oxidase Inhibitors; Nitriles; Oxidative Stress; Parkinson Disease; Selegiline | 2014 |
Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Receptors, Dopamine; Selegiline | 2003 |
[Mild cognitive impairment].
Topics: Aging; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Diagnosis, Differential; Disease Progression; Humans; Psychiatric Status Rating Scales; Selegiline; Severity of Illness Index; Vitamin E | 2003 |
Patient page. Slowing down a "slow" movement disorder: selegiline's benefit in treating Parkinson disease.
Topics: Disease Progression; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 2006 |
New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.
Topics: Binding Sites; Clinical Trials as Topic; Corpus Striatum; Disease Progression; gamma-Aminobutyric Acid; Humans; Mitochondria; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Neurotoxins; Nootropic Agents; Oxidative Stress; Parkinson Disease; Polyamines; Receptors, N-Methyl-D-Aspartate; Selegiline; Substantia Nigra | 1996 |
DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
Topics: Antioxidants; Antiparkinson Agents; Clinical Trials as Topic; Disease Progression; Humans; Neuroprotective Agents; Parkinson Disease; Selegiline; Vitamin E | 1998 |
Management of early Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Progression; Dopamine Agents; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline; Treatment Outcome | 1999 |
13 trial(s) available for selegiline and Disease Exacerbation
| Article | Year |
|---|---|
Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease.
Topics: Adult; Aged; Amyloid beta-Peptides; Antiparkinson Agents; Biomarkers; Disease Progression; Female; Humans; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Selegiline; tau Proteins | 2013 |
Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.
Topics: Adult; Aged; Aged, 80 and over; alpha-Synuclein; alpha-Tocopherol; Antiparkinson Agents; Cognition Disorders; Cohort Studies; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Selegiline | 2014 |
Effects of dopaminergic treatment on bladder function in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Disease Progression; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Sex Characteristics; Surveys and Questionnaires; Urinary Bladder Diseases; Urination Disorders; Urodynamics; Urologic Diseases | 2004 |
Selegiline slows the progression of the symptoms of Parkinson disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Time Factors | 2006 |
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group.
Topics: Aged; Antioxidants; Antiparkinson Agents; Disabled Persons; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Selegiline; Treatment Outcome; Vitamin E | 1996 |
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.
Topics: Aged; Antioxidants; Antiparkinson Agents; Disabled Persons; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Selegiline; Treatment Outcome; Vitamin E | 1996 |
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cognition; Disease Progression; Double-Blind Method; Drug Combinations; Female; Humans; Institutionalization; Male; Mental Status Schedule; Monoamine Oxidase Inhibitors; Proportional Hazards Models; Selegiline; Treatment Outcome; Vitamin E | 1997 |
Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Confidence Intervals; Disease Progression; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indoles; Longitudinal Studies; Male; Middle Aged; Odds Ratio; Parkinson Disease; Regression Analysis; Selegiline; Severity of Illness Index; Treatment Outcome | 1998 |
Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Disabled Persons; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Probability; Selegiline; Time Factors | 1998 |
DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
Topics: Antioxidants; Antiparkinson Agents; Clinical Trials as Topic; Disease Progression; Humans; Neuroprotective Agents; Parkinson Disease; Selegiline; Vitamin E | 1998 |
Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group.
Topics: Adult; Aged; Antiparkinson Agents; Denmark; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Norway; Parkinson Disease; Sample Size; Selegiline | 1999 |
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline; Substance Withdrawal Syndrome | 2000 |
Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Placebo Effect; Selegiline; Tocopherols | 2002 |
17 other study(ies) available for selegiline and Disease Exacerbation
| Article | Year |
|---|---|
[Primary prevention with enhancer substances for a longer and healthier life].
Topics: Aging; Antiparkinson Agents; Chronic Disease; Disease Progression; Education, Medical; Feeding Behavior; Humans; Hungary; Life Expectancy; Life Style; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Primary Prevention; Secondary Prevention; Selegiline; Tertiary Prevention | 2013 |
A Bayesian approach to joint analysis of multivariate longitudinal data and parametric accelerated failure time.
Topics: Bayes Theorem; Computer Simulation; Disease Progression; Drug Therapy, Combination; Humans; Longitudinal Studies; Markov Chains; Models, Statistical; Monte Carlo Method; Multivariate Analysis; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Tocopherols | 2014 |
Robust Bayesian hierarchical model using normal/independent distributions.
Topics: Bayes Theorem; Biometry; Disease Progression; Humans; Longitudinal Studies; Models, Statistical; Normal Distribution; Parkinson Disease; Selegiline | 2016 |
Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Astrocytes; Autoradiography; Brain; Disease Progression; Female; Gliosis; HLA Antigens; Humans; Immunohistochemistry; Isotope Labeling; Male; Microglia; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuritis; Radionuclide Imaging; Radiopharmaceuticals; Selegiline; Substrate Specificity; Up-Regulation | 2011 |
Selegiline use is associated with a slower progression in early Parkinson's disease as evaluated by Hoehn and Yahr Stage transition times.
Topics: Aged; Disability Evaluation; Disease Progression; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Proportional Hazards Models; Psychiatric Status Rating Scales; Selegiline | 2011 |
Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.
Topics: Antioxidants; Cholesterol; Disease Progression; Endpoint Determination; Female; Humans; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Randomized Controlled Trials as Topic; Selegiline; Tocopherols | 2011 |
Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.
Topics: Antiparkinson Agents; Cognition Disorders; Depression; Disability Evaluation; Disease Progression; Drug Substitution; Drug Therapy, Combination; Gait Disorders, Neurologic; Humans; Hypokinesia; Linear Models; Motor Activity; Nonlinear Dynamics; Parkinson Disease; Patient Dropouts; Postural Balance; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Selegiline; Sensation Disorders; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Tocopherols; Treatment Outcome; Tremor | 2012 |
Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Chi-Square Distribution; Cognition; Cognition Disorders; Depression; Disability Evaluation; Disease Progression; Humans; Kaplan-Meier Estimate; Middle Aged; Parkinson Disease; Patient Dropouts; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Selegiline; Severity of Illness Index; Time Factors; Tocopherols; Treatment Outcome | 2012 |
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.
Topics: Algorithms; Antiparkinson Agents; Bayes Theorem; Bromocriptine; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Models, Biological; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome | 2006 |
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.
Topics: Activities of Daily Living; Aged; Canada; Cognition Disorders; Cohort Studies; Depressive Disorder; Disease Progression; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Psychological Tests; Quality of Life; Randomized Controlled Trials as Topic; Retrospective Studies; Selegiline; Tocopherols; United States | 2008 |
Treatment of Parkinson's disease: disagreements.
Topics: Disease Progression; Humans; Levodopa; Parkinson Disease; Selegiline | 1997 |
Study suggests antioxidants slow decline in Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Disease Progression; Humans; Selegiline; Vitamin E | 1997 |
Selegiline and vitamin E in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Disease Progression; Drug Combinations; Humans; Neuroprotective Agents; Randomized Controlled Trials as Topic; Reproducibility of Results; Selegiline; Treatment Outcome; Vitamin E | 1997 |
Regulation of glutathione and cell toxicity following exposure to neurotropic substances and human immunodeficiency virus-1 in vitro.
Topics: AIDS Dementia Complex; Carrier Proteins; Cell Survival; Cells, Cultured; Cocaine; Disease Progression; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Glutathione; HIV-1; Humans; Macrophages; Membrane Glycoproteins; Membrane Transport Proteins; Morphine; Narcotics; Nerve Tissue Proteins; Oxidative Stress; Selegiline; Substance-Related Disorders; Tumor Cells, Cultured; Up-Regulation | 1997 |
Onset and progression of motor deficits in motor neuron degeneration (mnd) mice are unaltered by the glycine/NMDA receptor antagonist L-701,324 or the MAO-B inhibitor R(-)-deprenyl.
Topics: Animals; Disease Progression; Excitatory Amino Acid Antagonists; Female; Male; Mice; Mice, Mutant Strains; Monoamine Oxidase Inhibitors; Motor Activity; Motor Neuron Disease; Nerve Degeneration; Quinolones; Selegiline; Stereoisomerism | 1999 |
Parkinson's disease: therapeutic choices and timing decisions in patient management. Interview by Wayne Kuznar.
Topics: Age Factors; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Disease Progression; Drug Administration Schedule; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease; Patient Selection; Selegiline; Time Factors; Tolcapone | 1999 |
Freezing of gait in patients with advanced Parkinson's disease.
Topics: Adult; Age of Onset; Amantadine; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Female; Freezing; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Regression Analysis; Retrospective Studies; Selegiline | 2001 |